A healthcare company that develops treatment for lung diseases and injuries, Lung Therapeutics Inc., has received $1.5 million worth of funding from three investors. This is according to the most recent filing from SEC.
The company joined Austin Technology Incubator in March. ATI confirmed that Lung Therapeutics Inc. received $12 million to be used for the development of drug candidates. The budget came from National Institutes of Health.
Brian Windsor, company’s CEO, said that at the moment, their focus is treating complex pleural diseases. Individuals with this type of diseases are their main drug candidate that they want to treat.